NCT06005974

A Study of REC-4881 in Participants With Cancers Which Have an AXIN1 or APC Mutation

A Phase 2, Open Label Study of REC-4881 in Participants With Unresectable Locally Advanced or Metastatic Cancer With AXIN1 or APC Mutation

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 18 (actual)
• Sponsor: Recursion Pharmaceuticals Inc. · Industry
• Sex: All
• Age: 55 Years
• Healthy volunteers: Not accepted

Summary

This is a multi-center, open-label study to investigate the safety, efficacy and pharmacokinetics of REC-4881 (12 mg PO daily doses) for the treatment of participants with unresectable locally advanced or metastatic solid tumors with AXIN1 or APC mutation.

Conditions

• AXIN1 Gene Mutation
• APC Gene Mutation
• Solid Tumor

Interventions

Type	Name	Description
DRUG	REC-4881	REC-4881 4mg capsules

Timeline

• Start date: 2024-01-15
• Primary completion: 2025-02-24
• Completion: 2025-02-24
• First posted: 2023-08-23
• Last updated: 2026-02-23

Locations

13 sites across 1 country: United States

Regulatory

• FDA-regulated drug study